| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/03/2023 | -2.77% | Wedbush | → $72 | Reiterates | Neutral → Neutral |
| 07/21/2023 | -14.92% | Citigroup | $60 → $63 | Maintains | Sell |
| 05/02/2023 | -18.97% | Citigroup | $62 → $60 | Maintains | Sell |
| 03/29/2023 | -12.22% | UBS | $74 → $65 | Maintains | Neutral |
| 01/26/2023 | 5.33% | Wedbush | → $78 | Downgrades | Outperform → Neutral |
| 08/01/2022 | 16.14% | UBS | $72 → $86 | Maintains | Neutral |
| 07/27/2022 | 8.04% | Wells Fargo | $90 → $80 | Maintains | Equal-Weight |
| 07/15/2022 | -2.77% | UBS | $100 → $72 | Maintains | Neutral |
| 05/23/2022 | -8.17% | Citigroup | $110 → $68 | Downgrades | Buy → Sell |
| 04/27/2022 | 10.74% | B of A Securities | $120 → $82 | Downgrades | Buy → Underperform |
| 04/05/2022 | 28.29% | Wells Fargo | $105 → $95 | Maintains | Equal-Weight |
| 03/07/2022 | 51.25% | UBS | $110 → $112 | Maintains | Neutral |
| 03/07/2022 | 45.85% | Wedbush | → $108 | Upgrades | Neutral → Outperform |
| 02/28/2022 | 71.51% | Citigroup | $124 → $127 | Maintains | Buy |
| 10/05/2021 | 33.69% | Wedbush | → $99 | Initiates Coverage On | → Neutral |
| 05/03/2021 | 63.4% | B. Riley Securities | $113 → $121 | Maintains | Buy |
| 05/03/2021 | 62.05% | Monness, Crespi, Hardt | $100 → $120 | Maintains | Buy |
| 04/20/2021 | 52.6% | B. Riley Securities | $101 → $113 | Maintains | Buy |
| 01/13/2021 | 41.8% | Wells Fargo | → $105 | Downgrades | Overweight → Equal-Weight |
| 07/27/2020 | 24.24% | UBS | $86 → $92 | Maintains | Neutral |
| 07/27/2020 | 41.8% | Citigroup | $85 → $105 | Maintains | Buy |
| 06/11/2020 | 10.74% | UBS | $75 → $82 | Maintains | Neutral |
| 05/06/2020 | 18.84% | DA Davidson | $80 → $88 | Maintains | Buy |
| 05/06/2020 | 1.28% | UBS | $69 → $75 | Maintains | Neutral |
| 05/06/2020 | -0.07% | Deutsche Bank | $78 → $74 | Reiterates | → Hold |
| 05/05/2020 | 14.79% | CFRA | $110 → $85 | Maintains | Buy |
| 04/20/2020 | 14.79% | Citigroup | $90 → $85 | Maintains | Buy |
| 04/15/2020 | -6.82% | UBS | $101 → $69 | Maintains | Neutral |
| 03/30/2020 | 35.04% | Wells Fargo | $90 → $100 | Maintains | Overweight |
| 03/26/2020 | 35.04% | B. Riley Securities | $118 → $100 | Maintains | Buy |
| 03/16/2020 | 21.54% | Wells Fargo | $110 → $90 | Maintains | Overweight |
| 02/25/2020 | 28.29% | Deutsche Bank | $99 → $95 | Maintains | Hold |
| 12/18/2019 | 41.8% | UBS | $100 → $105 | Maintains | Neutral |
| 10/31/2019 | 59.35% | DA Davidson | $110 → $118 | Maintains | Buy |
| 10/02/2019 | — | DA Davidson | Upgrades | Neutral → Buy | |
| 04/24/2019 | — | DA Davidson | Initiates Coverage On | → Neutral | |
| 04/17/2019 | 33.69% | Deutsche Bank | → $99 | Initiates Coverage On | → Hold |
| 03/18/2019 | 62.05% | Citigroup | → $120 | Assumes | → Buy |
| 01/02/2019 | 32.34% | Wells Fargo | $105 → $98 | Maintains | Outperform |
| 12/03/2018 | 52.6% | Citigroup | $107 → $113 | Maintains | Buy |
| 11/02/2018 | — | Macquarie | Downgrades | Outperform → Neutral | |
| 10/22/2018 | 55.3% | Wells Fargo | $126 → $115 | Maintains | Outperform |
What is the target price for Carter's (CRI)?
The latest price target for Carter's (NYSE: CRI) was reported by Wedbush on August 3, 2023. The analyst firm set a price target for $72.00 expecting CRI to fall to within 12 months (a possible -2.77% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Carter's (CRI)?
The latest analyst rating for Carter's (NYSE: CRI) was provided by Wedbush, and Carter's reiterated their neutral rating.
When is the next analyst rating going to be posted or updated for Carter's (CRI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Carter's, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Carter's was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.
Is the Analyst Rating Carter's (CRI) correct?
While ratings are subjective and will change, the latest Carter's (CRI) rating was a reiterated with a price target of $0.00 to $72.00. The current price Carter's (CRI) is trading at is $74.05, which is out of the analyst's predicted range.